Title: A single arm, open label, signal-seeking, phase II trial of tepotinib in patients with advanced non-small cell lung cancer harbouring MET exon 14 skipping mutations detected by comprehensive genomic profiling.

Trial Summary:

The aim of this ASPiRATION and MoST substudy to evaluate the activity of tepotinib in metastatic non-squamous NSCLC with METex14 mutations detected by CGP

Supported By:

 

Eligibility:

Adult patients with newly diagnosed metastatic non-squamous NSCLC with METex14 skipping mutation identified using CGP.

Registration ID:

ACTRN12621000811808

Participation:

National

Status:

Recruiting

Activation Date:

23/09/2021

Study Chairs:

Associate Professor Chee Khoon Lee and Dr Shalini Subramaniam

Contact:

most.study@sydney.edu.au